Last reviewed · How we verify
Apatone®B
Apatone B is a small molecule that targets the mitochondrial permeability transition pore (mPTP) to prevent cell death.
Apatone B is a small molecule that targets the mitochondrial permeability transition pore (mPTP) to prevent cell death. Used for Acute myocardial infarction, Ischemic stroke.
At a glance
| Generic name | Apatone®B |
|---|---|
| Sponsor | IC-MedTech Corporation |
| Drug class | mPTP inhibitor |
| Target | mPTP |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the mPTP, Apatone B aims to reduce cell death in various tissues, including the heart and kidneys. This mechanism is thought to be beneficial in conditions characterized by cell death, such as ischemia-reperfusion injury.
Approved indications
- Acute myocardial infarction
- Ischemic stroke
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
- Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apatone®B CI brief — competitive landscape report
- Apatone®B updates RSS · CI watch RSS
- IC-MedTech Corporation portfolio CI